Table 3 Favourable and unfavourable viral outcomes by drug category
| Â | Favourable outcomesa n. of events (% of total outcomes by drug) | Unfavourable outcomes n. of events (% of total outcomes by drug) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs | Individuals n (% of total) | Individuals with 2 events | Fully suppressed (undetectable for study period) | Fully suppressed (became undetectable) | Transient rise | Adequate viral suppression | Total favourable outcomes | Viral breakthrough 1 log10 rise | Non-transient rise | Not suppressed | Total unfavourable outcomes |
All | 642 | 40 | 340(48.85) | 179(26.25) | 55(8.06) | 47(6.89) | 621(91.06) | 17(2.49) | 42(6.54) | 2(< 0.01%) | 61(8.94) |
First line therapy | |||||||||||
 Entecavir 0.5 mg | 407(63.40) | 22 | 216(50.35) | 118(27.21) | 35(8.16) | 27(3.96) | 396(92.31) | 8(1.86) | 24(5.90) | 1(<.01%) | 33(7.69) |
 Tenofovir | 143(22.27) | 11 | 61(39.61) | 48(31.17) | 10(6.49) | 19(2.79) | 138(89.61) | 6(3.90) | 9 (6.29) | 1(< 0.01%) | 16(10.39) |
Other | |||||||||||
 Entecavir 1 mg | 29(4.52) | 1 | 16(53.33) | 2(10.00) | 6(20.00) | 1(3.33) | 26(86.67) | 2(6.67) | 2(6.90) | 0(0.00) | 4(13.33) |
Older drugs | |||||||||||
 Lamivudine | 53(8.26) | 4 | 40(70.18) | 8(14.04) | 4(7.02) | 0(0.00) | 52(91.23) | 1(1.75) | 4(7.54) | 0(0.00) | 5(8.77) |
 Adefovir | 10(1.56) | 1 | 7(58.33) | 2(20.00) | 0(0.00) | 0(0.00) | 9(75.00) | 0(0.00) | 3(25.00) | 0(0.00) | 3(25.00) |